MedTech Mogrify extends Series A financing to 拢38m
Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has extended its Series A financing round to 拢38 million. The Cambridge firm says the funding will support further advancement of Mogrify鈥檚 pipeline through pre-clinical translation, continued platform optimisation, and facilitation of new and existing biopharma collaborations. … Continue reading MedTech Mogrify extends Series A financing to 拢38m
